key: cord-0729455-swobp44w authors: Masuko, Kayo title: Will the COVID‐19 pandemic trigger future occurrence of autoimmunity like Sjögren’s syndrome? date: 2021-06-22 journal: Int J Rheum Dis DOI: 10.1111/1756-185x.14154 sha: 57b3f3500501cbec6812517a1982cb9ead6ead7c doc_id: 729455 cord_uid: swobp44w nan (COVID-19) may include ground-glass opacity on chest radiography, coagulopathy, and other hematological abnormalities that resemble those found in autoimmune diseases. 3, 4 Autoantibodies, including anti-nuclear, anti-Sjögren's syndrome (SS)-A/Ro, anti-neutrophilic cytoplasmic, anti-cyclic peptide containing citrulline, and antiinterferon were detected in COVID-19 patients. [5] [6] [7] As for T cell immunity, long-term antigenic stimulation by SARS-CoV2 would induce T cell activation and exhaustion in both CD4+ and CD8+ T cells. 8, 9 Furthermore, a T-helper 17 (Th17) phenotype has been shown in COVID-19, as the T cells of patients with COVID-19 produce more IL-17 than those of controls. 9 T cell exhaustion and Th17 phenotype are characteristics found in autoimmune rheumatic diseases, such as in systemic lupus erythematosus (SLE). 10 In fact, a considerable number of COVID-19 patients were diagnosed as having autoimmune rheumatic diseases as they fulfilled the respective criteria. 4, 11, 12 In general, infection, either viral or bacterial, is recognized as the most critical factor to accelerate the incidence and/or disease activity of autoimmune diseases. For example, parvovirus, hepatitis virus, and Epstein-Barr virus (EBV) have been significant candidates as pathogens in autoimmune diseases such as SLE and SS. 13, 14 The precise mechanisms by which infection would accelerates autoimmunity are unclear; however, it may be plausible that infection evokes antiviral or antibacterial immune responses and activates inflammatory cytokines, which lead to a dysregulation of innate and adaptive immunity. Pusch et al 15 described that viruses induce "heterologous immunity" to the infected host, altering adaptive immune responses to viral and self-antigens. Moreover, EBV evokes B lymphocyte activation associated with overproduction of autoantibodies. 16 A "molecular mimicry" may exist between the viral antigen and autoantigen(s). 17, 18 Coxsackie virus, for example, has sequence homologies between the viral protein and an autoantigen, Ro60 peptide, which is often found in SS and other autoimmune diseases. 12 In addition, infections themselves, or the administration of antipathogenic agents, may alter the host's intestinal homeostasis, causing dysbiosis in the gut flora. Recent investigations suggest that the alteration of gut homeostasis, or dysbiosis, is crucial in the induction of autoimmune diseases. 19 For instance, the potential role of a species of Gram negative bacteria in oral and gut microbiota, that is, Prevotella spp., in the pathogenesis of rheumatoid arthritis is attracting widespread interest. 19, 20 As for SS, researchers have suggested an association between gut dysbiosis and the severity of dry eye. 21 Of note, in 2011, Shoenfeld et al 22 identified the concept of ASIA syndrome (autoimmune/inflammatory syndrome induced by adjuvants). The proposed syndrome encompasses a broad spectrum of autoimmunity that is induced after exposure to external factors such as infections. 22 Considering the time gap between exposure to an infection and autoimmune disease diagnosis, the authors hypothesized that "the non-antigenic activation" of immunity might determine the degree of autoimmune reaction after the infection. In the proposed entities for the diagnosis of "ASIA," "exposure to external stimuli" is one of the major criteria. According to the concept, SS is a typical example of "ASIA". 23 Considering these findings, the current pandemic of COVID-19 would evoke the occurrence of autoimmune rheumatic diseases such as SLE or SS, 24 which may constitute the ASIA syndrome. 12 To support this notion, it was observed that a significant number of patients with COVID-19 show clinical and laboratory findings similar to those in autoimmune rheumatic diseases. 24 The sequence homology between SARS-CoV-2 spike and nuclear proteins and human peptides has been demonstrated. 17, 18 Moreover, altered gut dysbiosis after SARS-CoV-2 infection has been reported, 25 Therefore, I propose that autoimmunity against the salivary glands should be carefully monitored, as SARS-CoV-2 infects human salivary glands as abundantly so that the saliva could be used as an excellent clinical sample for COVID-19 diagnosis. 29 The expression of ACE2, the SARS-CoV-2 receptor, was even higher in minor salivary glands than in the lungs. 30 After the infection, saliva may cultivate the live virus, and the salivary glands would act as a longterm viral reservoir of SARS-CoV-2. 30 Hence, autoimmune sialoadenitis, which is or at least mimics SS, might become apparent even after susceptible individuals recover from COVID-19 ( The speculation may not be limited to mRNA vaccines, as an association between specific vaccination (eg, influenza vaccine) and SS or the production of anti-Ro/anti-La antibodies has been reported. 23 Thus, the infection and/or vaccination might trigger or accelerate autoimmune responses against the spike protein of the SARS-CoV-2 in genetically susceptible individuals or patients with immune dysfunction. In this concern, not only autoimmune rheumatic diseases but also other autoimmunity entities such as hepatitis 33 and thyroiditis 34 have been reported to emerge after vaccination against SARS-CoV-2. Therefore, the potential stimulatory effect of SARS-CoV-2 vaccines (regardless of mRNA, virus vectored, or protein subunit) to brake immunological tolerance should be examined for both short-and long-term events. Nevertheless, considering the severe outcome of COVID-19, vaccinations should be processed under a balance between the risk and the benefit for each individual in this pandemic. 32 https://orcid.org/0000-0001-6058-6363 F I G U R E 1 Severe acute respiratory syndrome coronavirus 2 infection with potential of developing Sjögren's syndrome Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review SARS-CoV-2 infection as a trigger of autoimmune response Autoantibodies in COVID-19: frequency and function High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review: high levels of anti-SSA/Ro antibodies in COVID-19 Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia T-cell responses and therapies against SARS-CoV-2 infection Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis? SARS-CoV-2, the autoimmune virus Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals Respiratory virus-induced heterologous immunity: part of the problem or part of the solution? The role of Epstein-Barr virus infection in primary Sjögren's syndrome Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine Intestinal microbes in autoimmune and inflammatory disease Diet, microbiota, and gut permeability-the unknown triad in rheumatoid arthritis Gut dysbiosis is prevailing in Sjögren's syndrome and is related to dry eye severity ASIA'-autoimmune/inflammatory syndrome induced by adjuvants Classical examples of the concept of the ASIA syndrome Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19 MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. Rheumatology (Oxford) Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents Saliva is a reliable tool to detect SARS-CoV-2 Salivary glands: potential reservoirs for COVID-19 asymptomatic infection COVID's toll on smell and taste: what scientists do and don't know Do COVID-19 RNA-based vaccines put at risk of immunemediated diseases? In reply to 'potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? Two cases of Graves' disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants How to cite this article: Masuko K. Will the COVID-19 pandemic trigger future occurrence of autoimmunity like Sjögren's syndrome?